Does the Form 3 for Alto Neuroscience indicate any indirect holdings or related entities?

The provided excerpt does not list any indirect holdings or related entities. The transactions array is empty, and the single reporting person, director Andrew Craig Miller, has no associated transactions or derivative positions in this data snapshot.

Alto Neuroscience director files initial Form 3

Q: What does Andrew Craig Miller’s Form 3 for ANRO show?

The Form 3 shows that Andrew Craig Miller is a director of Alto Neuroscience, Inc. In this excerpt, there are no reported common stock or derivative holdings and no insider transactions such as purchases, sales, or option exercises.

Q: What is the significance of a Form 3 filing for Alto Neuroscience, Inc. (ANRO)?

A Form 3 is an initial statement of beneficial ownership for company insiders. Here, it mainly records that Andrew Craig Miller is a director of Alto Neuroscience, Inc., with no trades or existing holdings disclosed in the excerpted data.

Alto Neuroscience, Inc. director Andrew Craig Miller filed an initial Form 3 reporting his status as a director of the company.

Accepted by SEC EDGAR 05/29/2026 - 04:15 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Alto Neuroscience, Inc. director Andrew Craig Miller filed an initial Form 3 reporting his status as a director of the company. The excerpt shows no reported common stock or derivative holdings and no buy, sell, or other insider transactions associated with this filing.

Key Figures

Buy shares reported: 0 shares Sell shares reported: 0 shares Exercise shares reported: 0 shares +1 more

4 metrics

Buy shares reported 0 shares Form 3 transaction summary buyShares

Sell shares reported 0 shares Form 3 transaction summary sellShares

Exercise shares reported 0 shares Form 3 transaction summary exerciseShares

Derivative transactions 0 transactions Form 3 transaction summary derivativeTransactionCount

Key Terms

Form 3, reportingPersons, transactionSummary, derivativeSummary

4 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Miller Andrew Craig""

transactionSummary financial

""transactionSummary": { "buyCount": 0, "sellCount": 0"

derivativeSummary financial

""derivativeSummary": [],"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Andrew Craig Miller’s Form 3 for ANRO show?

The Form 3 shows that Andrew Craig Miller is a director of Alto Neuroscience, Inc. In this excerpt, there are no reported common stock or derivative holdings and no insider transactions such as purchases, sales, or option exercises.

Did Andrew Craig Miller buy or sell Alto Neuroscience (ANRO) shares in this Form 3?

No insider share purchases or sales are reported in this Form 3. The transaction summary lists zero buy shares, sell shares, exercises, gifts, tax withholdings, or restructuring entries, indicating no trading activity in this specific filing excerpt.

Are there any derivative securities reported for ANRO in this Form 3?

No derivative securities are shown in this Form 3 excerpt. The derivativeSummary is empty and the transaction summary reports zero derivative transactions and zero exercise shares, indicating no options, warrants, or similar instruments are detailed here.

What is the significance of a Form 3 filing for Alto Neuroscience, Inc. (ANRO)?

A Form 3 is an initial statement of beneficial ownership for company insiders. Here, it mainly records that Andrew Craig Miller is a director of Alto Neuroscience, Inc., with no trades or existing holdings disclosed in the excerpted data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Miller Andrew Craig

(Last)

(First)

(Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW

CALIFORNIA

94041

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/27/2026

3. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

No securities beneficially owned.

No securities are beneficially owned.

	/s/ Erin R. McQuade, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR